CB1 cannabinoid receptor ligands.

Ganesh A Thakur; Spyros P Nikas; Alexandros Makriyannis

doi:10.2174/1389557054368772

Home/Archive/PubMed

PubMed · 16026309

CB1 cannabinoid receptor ligands.

Ganesh A Thakur·Spyros P Nikas·Alexandros Makriyannis

View original source ↗Export metadata ↓

Abstract

The CB1 receptor is expressed in the central nervous system and numerous other tissues including heart, lung and uterus and has been recognized as an important therapeutic target for pain, appetite modulation, glaucoma, multiple sclerosis and other indications. An interesting feature of this GPCR is its ability to be activated by a number of structurally different classes of compounds, thus, raising the possibility of multiple activated forms of the receptor. Understanding of the structure-activity relationships of cannabinergic ligands has paved the road for the development of novel ligands exhibiting receptor subtype selectivity and efficacy. This review highlights the important CB1 cannabinergic ligands developed to date.

Explore related subjects

Appetite Stimulants Cannabinoids Central Nervous System Glaucoma Humans Ligands Multiple Sclerosis Pain Receptor, Cannabinoid, CB1 Structure-Activity Relationship Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Ganesh A Thakur, Spyros P Nikas, Alexandros Makriyannis. 2005. CB1 cannabinoid receptor ligands.. https://doi.org/10.2174/1389557054368772

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Involuntary weight loss: interview with Lisa Capaldini, M.D.

This short overview looks at some of the major considerations in treating involuntary weight loss of people with HIV, in 2005.

Appetite Stimulants↗

PubMed2005

Treatment of unintentional weight loss in patients with cancer.

Malnutrition from anorexia and reduced nutrient intake is common in patients with cancer. Abnormalities in gastrointestinal function caused by the tumor or treatment of the tumor may be direct causes for nutrition challenges. However, other patients may present with cancer cachexia, a wasting syndrome characterized by weight loss, anorexia, early satiety, progressive debilitation, and malnutrition that results in a greater risk of organ dysfunction and death. Changes in host metabolism and energy expenditure are thought to contribute to the development of cachexia, although this relationship is not clear. There is evidence that the etiology of these metabolic changes may be mediated by a neurohormonal response stimulated by the tumor. Because a single cause for these metabolic abnormalities has not been identified, several approaches to treatment of cancer cachexia have been reported. After correction of any underlying gastrointestinal abnormalities, single nutrients or other pharmacologic agents have been used in an attempt to favorably affect appetite or counter metabolic abnormalities that cause inefficient nutrient use. A variety of agents have been studied for their positive effects on appetite, including progestational agents, glucocorticoids, cannabinoids, cyproheptadine, olanzapine, and mirtazapine. Other agents have been investigated for their anti-inflammatory properties, including thalidomide, pentoxyphylline, melatonin, and omega-3 fatty acids. Anabolic agents such as testosterone derivatives have been investigated as well. The decision to treat symptoms of cancer cachexia should be based on the patient's desires and current medical condition. Choice of the most appropriate agent to treat unintentional weight loss in patients with cancer should include consideration of effects on appetite, weight, quality of life, and risk of adverse effects according to current evidence-based medicine, and cost and availability of the agent.

Appetite Stimulants↗

PubMed2004

The pharmacological treatment of cachexia.

Cachexia is a complex syndrome. The main components of this pathological state are anorexia and metabolic abnormalities such as glucose intolerance, fat depletion, and muscle protein catabolism among others. The aim of the present article is to review the different therapeutic approaches that have been designed to fight and counteract muscle wasting in different pathological states such as cancer, AIDS and chronic heart failure.

Appetite Stimulants↗